Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A

Zhujun Deng1, Yun Qin2, Yongmei Liu3

  • 1Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Precision Medicine Key Laboratory of Sichuan Province, Precision Medicine Center, West China Hospital, Sichuan University, Chengdu, China.

Clinical Lung Cancer
|October 17, 2020
PubMed
Abstract

Insights

Adding antiangiogenic agents to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) improved progression-free survival for EGFR-mutant non-small-cell lung cancer (NSCLC). However, this combination therapy increased the risk of serious adverse events without improving overall survival or response rates.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Combination therapy with antiangiogenic agents and EGFR TKIs is explored for EGFR-mutant NSCLC.
  • Controversy exists regarding the efficacy and safety of these combinations.
  • Recent Phase III trials have reported outcomes not yet included in meta-analyses.

Purpose of the Study:

  • To compare the efficacy and safety of antiangiogenic agents plus EGFR TKIs versus EGFR TKIs alone in EGFR-mutant NSCLC.
  • To evaluate progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events (AEs).

Main Methods:

  • A meta-analysis was conducted on 6 randomized controlled trials and 1 prospective cohort study.
  • In total, 1295 patients with EGFR-mutant NSCLC were included.
  • Outcomes analyzed included PFS, OS, ORR, and AEs.

Main Results:

  • Combination therapy significantly improved PFS (HR, 0.58; 95% CI, 0.50-0.67; P < .001).
  • No significant differences were observed in OS (HR, 0.79; 95% CI, 0.53-1.18; P = .26) or ORR (RR, 1.03; 95% CI, 0.97-1.10; P = .30).
  • A higher risk of serious AEs was noted with combination therapy (RR, 1.41; 95% CI, 1.11-1.79; P = .005).

Conclusions:

  • Antiangiogenic agents plus EGFR TKIs enhance PFS in EGFR-mutant NSCLC.
  • This combination therapy is associated with an increased risk of serious adverse events.
  • No significant improvements in OS or ORR were demonstrated for the combination therapy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
309
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
345
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K